Navigation Links
Texas State Tests Potential New Cancer-Fighting Weapon
Date:10/12/2009

SAN MARCOS, Texas, Oct. 12 /PRNewswire/ -- Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

Dhiraj Vattem, professor in the Department of Family and Consumer Sciences, and Reed Richardson, professor in the Department of Agriculture, supervised the tests in cooperation with Orizon Research. Results were announced at a University press conference.

The product, known as ALKA-V6, is a proprietary modified silicon-based compound developed by Orizon Research. The in-vitro evaluations will be followed by a second phase of testing for ALKA-V6 which will consist of end-point evaluations in in-vivo systems. Results from second-phase testing are expected within the next 12 months.

The anticancer studies revealed ALKA-V6:

  • prevented attachment of cancer cells
  • (a 1:40 dilution) completely killed all colon cancer cells (100% lethality)
  • reduced harmful mutations in the DNA
  • induced apoptosis (programmed cell death)
  • stimulated important antioxidant enzymes

The anti-retroviral studies revealed ALKA-V6:

  • increased nitric oxide dependent anti-viral effects
  • inhibited enzymes important in viral assembly, metabolism, and replication
  • caused changes in the surface carbohydrate composition and metabolism
  • inhibited the activity of the enzyme responsible for reverse transcription

The unique electrochemical and structural composition of ALKA-V6 indicates that it may provide an alternative basis for control of cancer cell growth and virus survival. However, this implication is based solely on in-vitro results and end-point in-vivo evaluations are imperative.

Orizon Research Institute of Odessa, Texas is the international distributor of ALKA V-6, which is currently being sold as a nutritional supplement on the company web site. The entire research study is also available on the Orizon Research web site at www.orizonresearch.com.

SOURCE Orizon Research Institute


'/>"/>
SOURCE Orizon Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries
2. Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration
3. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
4. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
5. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
6. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
7. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
8. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
9. Iowas Largest Health System Launches First-in-the-Nation Statewide Electronic Prescribing
10. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
11. Newly Updated Pharmacy State Law Compendium Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):